oncbrain — oncology meeting digest

PrTK03 (aglatimagene besadenovec + EBRT)

Thu, 04 Jun 2026 00:00:00 GMT

[Practice-changing] DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer. Eligible: Intermediate/high-risk localized prostate cancer, ECOG 0–2, planning definitive

mRCAT-III

Tue, 02 Jun 2026 00:00:00 GMT

[Early signal] pCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC. Eligible: pMMR/MSS LARC, cT3-4N0/+M0, tumor ≤10cm from anal verge, no positive lateral LN

Breast RT + Systemic Therapy Concurrency Review (Speers)

Tue, 02 Jun 2026 00:00:00 GMT

[Confirmatory] T-DXd ILD 9.6% vs T-DM1 1.6% (DESTINY-Breast05); ASCO26 PK-guided concurrency framework for breast RT + systemic agents.

CAN-2409

Sun, 31 May 2026 00:00:00 GMT

[Early signal] DFS HR 0.70 vs placebo (p=0.0155), driven by 2yr biopsy pCR 80.4% vs 63.6%; OS/PCSM immature at 50.3mo. Eligible: High/intermediate-risk localized prostate cancer, RT 78Gy

MIRACLE-2

Sun, 31 May 2026 00:00:00 GMT

[Early signal] 68% ORR, median OS 23.2mo, 18% NED in MSS unresectable metastatic rectal ca (N=50). Eligible: MSS unresectable metastatic rectal cancer, synchronous mets, first-line

RAD-IO

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 12-month DFS 80% (40/50; 95% CI 0.67-0.89) with durvalumab + chemoRT in MIBC, clearing GO threshold ≥75%; single-arm. Eligible: MIBC cT2-T3, 13% node-positive, 75% prior neoadjuvant chemo, median age 69

MIBC Management Post-pCR / Bladder-Sparing Session

Sat, 30 May 2026 00:00:00 GMT

[Early signal] Durvalumab + CRT (55 Gy/20 fr) feasible in 54 MIBC (87% full RT); pCR after NAC carries 85% 5-yr OS per SWOG 8710. Eligible: MIBC (cT2-4a N0), curative-intent bladder-sparing candidates

Neo-CRAG

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] Adding neoadj CRT to peri-op XELOX: mDFS 52.7 vs 24.4 mo, mOS 67.5 vs 37.6 mo in high-risk LAGC. Eligible: Locally advanced gastric/GEJ adenocarcinoma (cT3N2+, T4), peri-op XELOX eligible

SWOG/NRG S1914

Tue, 26 May 2026 00:00:00 GMT

[Confirmatory] No OS benefit from adding atezolizumab to SBRT (HR 1.15, p=0.63); closed for futility; G≥3 AEs 12% vs 2%. Eligible: Inoperable early-stage NSCLC T1-3N0M0 ≤7cm, ≥1 recurrence risk factor

Bladder-preserving TMT for MIBC: prognostic factors (ESTRO 2026)

Tue, 19 May 2026 00:00:00 GMT

[Confirmatory] CLR 63.7% in 369 MIBC pts on TMT; 5-FU-based CRT (OR 4.9) and portal imaging frequency independently predicted CLR. Eligible: cT2-T4aNOMO MIBC, median age 76, selected for organ-preserving TMT

RADIOSA

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] Post-hoc: SBRT + 6mo ADT vs SBRT alone in oligorecurrent prostate; median MFS 16.6mo vs NR, HR 0.39, p=0.0012. Eligible: Oligorecurrent prostate cancer, SBRT candidates, median f/u ~4yr